Relative Bioavailability of Omaveloxolone When Capsules Are Sprinkled Over and Mixed in Applesauce Compared With Administration as Intact Omaveloxolone Capsules: A Phase 1, Randomized, Open‐Label, Single‐Dose, Crossover Study in Healthy Adults
Authors:
Open Access
- 4 June 2024
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (10) , 1304-1311
Abstract
Omaveloxolone (SKYCLARYS®) is approved for the treatment of Friedreich ataxia (FA) in patients aged ≥16 years in the United States and European Union (EU). The recommended dosage is 150 mg administered orally once daily as three 50‐mg capsules. However, some patients with FA may have oropharyngeal dysphagia or difficulty swallowing whole capsules; therefore, alternate method(s) of administration are needed. A Phase 1 clinical study in 32 healthy volunteers evaluated the relative bioavailability, safety, and tolerability of a single dose of omaveloxolone when capsule contents were sprinkled on and mixed in applesauce compared to when taken as intact capsules. Palatability when sprinkled on and mixed in applesauce was assessed with a questionnaire. After a single 150‐mg dose, the peak and overall exposures of omaveloxolone were similar irrespective of administration method, with the 90% CIs of the geometric least squares mean ratio (%) for maximum plasma concentration (Cmax), AUC0‐t, and AUC0‐∞ within the 80% to 125% reference intervals. Omaveloxolone was absorbed more slowly as intact capsules (median tmax, 10 h) compared with sprinkled capsule contents over applesauce (median tmax, 6 h). With chronic daily administration of omaveloxolone to treat FA, the 4‐h difference in tmax is not considered clinically relevant. Sprinkled omaveloxolone capsule contents on applesauce were well tolerated, with acceptable palatability and no serious adverse events. Given the similar systemic exposure when capsules were swallowed whole, sprinkling omaveloxolone capsule contents on and mixing in applesauce is a feasible alternative method of administering omaveloxolone and has been included in both the United States and EU prescribing information.Keywords
This publication has 19 references indexed in Scilit:
- Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe ExtensionMovement Disorders, 2022
- Antioxidant defense mechanisms and its dysfunctional regulation in the mitochondrial disease, Friedreich's ataxiaFree Radical Biology and Medicine, 2020
- Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)Annals of Neurology, 2020
- Sprinkle formulations—A review of commercially available productsAsian Journal of Pharmaceutical Sciences, 2020
- Changes detected in swallowing function in Friedreich ataxia over 12 monthsNeuromuscular Disorders, 2019
- Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxiaAnnals of Clinical and Translational Neurology, 2018
- The multifaceted role of Nrf2 in mitochondrial functionCurrent Opinion in Toxicology, 2016
- The Nrf2 regulatory network provides an interface between redox and intermediary metabolismTrends in Biochemical Sciences, 2014
- Friedreich's ataxia: Pathology, pathogenesis, and molecular geneticsJournal of the Neurological Sciences, 2011
- Nrf2–Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen speciesAdvances in Enzyme Regulation, 2006